Press Releases

09/06/2016 Publication of the 2015 Reference Document

24/02/2016 OSE PHARMA and EFFIMUNE Announce Proposed Merger to Create Significant Immunotherapy Player

29/03/2016 OSE Pharma to attend the Small & Midcap Event in Paris on 11 & 12 April

21/03/2016 2015 Annual Results in Line with Forecasts, and Significant Clinical Advances

22/02/2016 First patients enrolled and dosed in the pivotal trial of Phase 3 of Tedopi®

04/02/2016 OSE Pharma Announces U.S. Initiation of Atalante 1 in NSCLC

06/01/2016 OSE Pharma Announces Initiation of its Pivotal Phase 3 trial of Tedopi® in NSCLC

05/01/2016 OSE Pharma announces its events for Q1 2016

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15